A man who says he got 'Ozempic penis' from the weight loss drug Wegovy has opened up on how his sex life has been going ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

GLP-1 weight-loss drugs are popular but pricey. New data highlights use by age and gender - and why interest outpaces access for many.

Eli Lilly, the manufacturer of a new weight-loss pill (an alternative to popular weight-loss jabs), says the drug could be ...

Novo Nordisk shares jumped more than 5% on Friday, extending Thursday’s rally, after Eli Lilly’s obesity pill data fell short of market expectations.

(Reuters) -European shares edged higher and were on track for their biggest weekly gain in 12 as investors assessed U.S.

Shares of Eli Lilly plunged after the drug maker reported less-than-stellar results of a new study of an experimental anti-obesity pill that is expected to become a blockbuster. The pill helped people ...

Shares of Eli Lilly & Co. suffered their biggest selloff in 26 years on Thursday, after the drug giant disclosed late-stage trial data for its weight-loss pill that fell well short of expectations.

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Some studies have linked the popular weight-loss drugs with a potentially higher risk of eye problems and vision loss. Should ...